{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:10:45Z","timestamp":1789153845629,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Brasileira de Reumatologia (English Edition)"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.rbre.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T05:45:22Z","timestamp":1491543922000},"page":"346-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Critical revision of the medical treatment of gout in Brazil"],"prefix":"10.1016","volume":"57","author":[{"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maicon Piana","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan Marostica","family":"Catholino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo dos Santos","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor Andrei","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldo da Rocha Castelar","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rbre.2017.03.002_bib0530","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0535","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s12325-012-0059-z","article-title":"Evaluation and treatment of gout as a chronic disease","volume":"29","author":"Perez-Ruiz","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.rbre.2017.03.002_bib0540","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.rbre.2017.03.002_bib0545","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.rbre.2017.03.002_bib0550","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1080\/15257770802138558","article-title":"Uric acid: the oxidant\u2013antioxidant paradox","volume":"27","author":"Sautin","year":"2008","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.rbre.2017.03.002_bib0555","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0560","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","article-title":"Regulation of uric acid excretion by the kidney","volume":"14","author":"Lipkowitz","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.rbre.2017.03.002_bib0565","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.rdc.2014.01.003","article-title":"Clinical manifestations and diagnosis of gout","volume":"40","author":"Perez-Ruiz","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rbre.2017.03.002_bib0570","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3904\/kjim.2014.29.3.361","article-title":"Clinical factors and treatment outcomes associated with failure in the detection of urate crystal in patients with acute gouty arthritis","volume":"29","author":"Park","year":"2014","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0575","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/archinte.168.10.1104","article-title":"Long-term cardiovascular mortality among middle-aged men with gout","volume":"168","author":"Krishnan","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0580","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/qjmed\/hct083","article-title":"Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality","volume":"106","author":"Stack","year":"2013","journal-title":"QJM"},{"key":"10.1016\/j.rbre.2017.03.002_bib0585","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/ard.2006.055251","article-title":"EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0590","doi-asserted-by":"crossref","first-page":"e003659","DOI":"10.1136\/bmjopen-2013-003659","article-title":"Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women","volume":"3","author":"Maruhashi","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.rbre.2017.03.002_bib0595","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10067-014-2520-7","article-title":"The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort","volume":"33","author":"Duskin-Bitan","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0600","doi-asserted-by":"crossref","first-page":"63","DOI":"10.11613\/BM.2012.007","article-title":"Review. Uric acid as one of the important factors in multifactorial disorders \u2013 facts and controversies","volume":"22","author":"Pasalic","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0605","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.rdc.2014.01.001","article-title":"Epidemiology of gout","volume":"40","author":"Roddy","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rbre.2017.03.002_bib0610","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.107.703389","article-title":"Independent impact of gout on mortality and risk for coronary heart disease","volume":"116","author":"Choi","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.rbre.2017.03.002_bib0615","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0620","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrrheum.2014.32","article-title":"Optimizing current treatment of gout","volume":"10","author":"Rees","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0625","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RHU.0b013e31827d8790","article-title":"Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis","volume":"19","author":"Cronstein","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0630","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.reuma.2012.06.014","article-title":"Uso de recursos e impacto econ\u00f3mico de los pacientes con gota: estudio multic\u00e9ntrico de \u00e1mbito poblacional","volume":"9","author":"Sicras-Mainar","year":"2013","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.rbre.2017.03.002_bib0635","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCULATIONAHA.107.728600","article-title":"Podagra, uric acid, and cardiovascular disease","volume":"116","author":"Alderman","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.rbre.2017.03.002_bib0640","doi-asserted-by":"crossref","first-page":"230","DOI":"10.7326\/0003-4819-86-2-230","article-title":"The pathogenesis of podagra","volume":"86","author":"Simkin","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0645","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jbspin.2011.12.006","article-title":"GOSPEL: Prospective survey of gout in France. Part I: design and patient characteristics (n=1003)","volume":"79","author":"Liot\u00e9","year":"2012","journal-title":"Bone Spine"},{"key":"10.1016\/j.rbre.2017.03.002_bib0650","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0655","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/rheumatology\/kem246","article-title":"Tophaceous joint disease strongly predicts hand function in patients with gout","volume":"46","author":"Dalbeth","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.rbre.2017.03.002_bib0660","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/art.22891","article-title":"Validation of a radiographic damage index in chronic gout","volume":"57","author":"Dalbeth","year":"2007","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0665","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0670","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0033-8389(03)00158-1","article-title":"Gout: a clinical and radiologic review","volume":"42","author":"Monu","year":"2004","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.rbre.2017.03.002_bib0675","first-page":"427","article-title":"Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States","volume":"16","author":"Lawrence","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0680","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.23176","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II","volume":"58","author":"Lawrence","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0685","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1001\/jama.1991.03470210072035","article-title":"Incidence and risk factors for gout in white men","volume":"266","author":"Roubenoff","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.03.002_bib0690","first-page":"199","article-title":"Gout and its comorbidities","volume":"68","author":"Pillinger","year":"2010","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0695","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.rbre.2017.03.002_bib0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2006.01.020","article-title":"Alcohol consumption as a trigger of recurrent gout attacks","volume":"119","author":"Zhang","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0705","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0710","doi-asserted-by":"crossref","first-page":"e99102","DOI":"10.1371\/journal.pone.0099102","article-title":"Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study","volume":"9","author":"Kok","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.rbre.2017.03.002_bib0715","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/art.27338","article-title":"Epidemiology of gout in women: fifty-two-year followup of a prospective cohort","volume":"62","author":"Bhole","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0720","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/annrheumdis-2013-203779","article-title":"Revisiting comorbidities in gout: a cluster analysis","volume":"74","author":"Richette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0725","doi-asserted-by":"crossref","first-page":"e39321","DOI":"10.1371\/journal.pone.0039321","article-title":"Serum uric acid and adiposity: deciphering causality using a bidirectional mendelian randomization approach","volume":"7","author":"Lyngdoh","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rbre.2017.03.002_bib0730","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/sj.ejcn.1601364","article-title":"Obesity, weight change, and risks for hypertension, diabetes, and hypercholesterolemia in Japanese men","volume":"56","author":"Ishikawa-Takata","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.rbre.2017.03.002_bib0735","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/BOR.0b013e328335ef38","article-title":"A prescription for lifestyle change in patients with hyperuricemia and gout","volume":"22","author":"Choi","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0740","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/qjmed\/hcr242","article-title":"Recent advances in management of gout","volume":"105","author":"Suresh","year":"2012","journal-title":"QJM"},{"key":"10.1016\/j.rbre.2017.03.002_bib0745","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.37925","article-title":"Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial","volume":"65","author":"Stamp","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0750","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/art.22712","article-title":"Coffee consumption and risk of incident gout in men a prospective study","volume":"56","author":"Choi","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0755","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/annrheumdis-2014-206364","article-title":"Performance of classification criteria for gout in early and established disease","volume":"75","author":"Taylor","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0760","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/rheumatology\/kev017","article-title":"The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study","volume":"54","author":"Kienhorst","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0765","first-page":"248","article-title":"Influence of the natural history of disease on a previous diagnosis in patients with gout","volume":"5","author":"P\u00e9rez Ruiz","year":"2009","journal-title":"Reumatol Cl\u00ednica (English Ed)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0770","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0775","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.autrev.2009.05.001","article-title":"The importance of inflammation and vitamin D status in SLE-associated osteoporosis","volume":"9","author":"Alele","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.rbre.2017.03.002_bib0780","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0785","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.rbre.2017.03.002_bib0790","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/ard.2006.060368","article-title":"Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0795","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.rdc.2014.01.008","article-title":"Treatment of acute gout","volume":"40","author":"Schlesinger","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rbre.2017.03.002_bib0800","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0805","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.rbre.2017.03.002_bib0810","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/rheumatology\/keh640","article-title":"Mechanisms of inflammation in gout","volume":"44","author":"Dalbeth","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0815","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/2040622312462056","article-title":"Latest evidence on gout management: what the clinician needs to know","volume":"3","author":"Burns","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0820","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.3760\/cma.j.issn.0366-6999.20122892","article-title":"Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial","volume":"126","author":"Li","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.rbre.2017.03.002_bib0825","unstructured":"National T, Centre C. National clinical guideline for care and management in adults."},{"key":"10.1016\/j.rbre.2017.03.002_bib0830","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Seminars Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0835","first-page":"145","article-title":"The year in gout: 2011\u20132012","volume":"70","author":"Crittenden","year":"2012","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0840","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1006\/phrs.2002.0969","article-title":"Molecular mechanisms of immunomodulatory activity of glucocorticoids","volume":"45","author":"Riccardi","year":"2002","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0845","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rbre.2017.03.002_bib0850","first-page":"696","article-title":"ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems","volume":"21","author":"Ritter","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0855","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.semarthrit.2013.09.006","article-title":"ACTH as a treatment for acute crystal-induced arthritis: update on clinical evidence and mechanisms of action","volume":"43","author":"Daoussis","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0860","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.1780310618","article-title":"Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout","volume":"31","author":"Axelrod","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rbre.2017.03.002_bib0865","first-page":"230","article-title":"The mechanisms of inflammation in gout and pseudogout (CPP-induced arthritis)","volume":"63","author":"Busso","year":"2011","journal-title":"Reumatism"},{"key":"10.1016\/j.rbre.2017.03.002_bib0870","doi-asserted-by":"crossref","first-page":"e50559","DOI":"10.1371\/journal.pone.0050559","article-title":"Pre-treatment with allopurinol or uricase attenuates barrier dysfunction but not inflammation during murine ventilator-induced lung injury","volume":"7","author":"Kuipers","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.rbre.2017.03.002_bib0875","doi-asserted-by":"crossref","first-page":"R25","DOI":"10.1186\/ar4159","article-title":"Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator","volume":"15","author":"Terkeltaub","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rbre.2017.03.002_bib0880","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2013-204575","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0885","first-page":"331","article-title":"Local ice therapy during bouts of acute gouty arthritis","volume":"29","author":"Schlesinger","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0890","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/annrheumdis-2012-201676","article-title":"Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study","volume":"72","author":"Rees","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0895","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/annrheumdis-2011-200801","article-title":"Patient and provider barriers to effective management of gout in general practice: a qualitative study","volume":"71","author":"Spencer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0900","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rdc.2014.01.012","article-title":"Long-term management of gout: nonpharmacologic and pharmacologic therapies","volume":"40","author":"Chaichian","year":"2014","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.rbre.2017.03.002_bib0905","first-page":"1341","article-title":"Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study","volume":"33","author":"Hunter","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0910","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case\u2013control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.rbre.2017.03.002_bib0915","first-page":"1383","article-title":"Withdrawal of longterm antihyperuricemic therapy in tophaceous gout","volume":"20","author":"Van Lieshout-Zuidema","year":"1993","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0920","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/art.22232","article-title":"Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study","volume":"55","author":"Perez-Ruiz","year":"2006","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0925","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1038\/srep04554","article-title":"Xanthine oxidase inhibition by febuxostat attenuates experimental atherosclerosis in mice","volume":"4","author":"Nomura","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.rbre.2017.03.002_bib0930","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.2012.04207.x","article-title":"The pharmacokinetics of oxypurinol in people with gout","volume":"74","author":"Stocker","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0935","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1185\/03007995.2011.563284","article-title":"A new perspective on the pharmacoeconomics of colchicine","volume":"27","author":"Wertheimer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.rbre.2017.03.002_bib0940","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0945","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0950","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/acr.21817","article-title":"Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0955","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2474-13-180","article-title":"Patients\u2019 knowledge and beliefs concerning gout and its treatment: a population based study","volume":"13","author":"Harrold","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.rbre.2017.03.002_bib0960","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3899\/jrheum.101156","article-title":"Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors","volume":"38","author":"Goldfarb","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0965","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rbre.2017.03.002_bib0970","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for mmanagement of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.rbre.2017.03.002_bib0975","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11535770-000000000-00000","article-title":"Febuxostate for the management of hyperuricaemia in patients with gout: a nice single technology appraisal","volume":"29","author":"Stevenson","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.rbre.2017.03.002_bib0980","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/BOR.0000000000000035","article-title":"Uricosuric drugs: the once and future therapy for hyperuricemia?","volume":"26","author":"Bach","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib0985","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rbre.2017.03.002_bib0990","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinternmed.2008.606","article-title":"Vitamin C intake and the risk of gout in men: a prospective study","volume":"169","author":"Choi","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.rbre.2017.03.002_bib0995","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00163854","article-title":"Two independent mutational events in the loss of urate oxidase during hominoid evolution","volume":"34","author":"Wu","year":"1992","journal-title":"J Mol Evol"},{"key":"10.1016\/j.rbre.2017.03.002_bib1000","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.addr.2007.06.011","article-title":"PEG-uricase in the management of treatment-resistant gout and hyperuricemia","volume":"60","author":"Sherman","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.rbre.2017.03.002_bib1005","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rbre.2017.03.002_bib1010","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar1861","article-title":"Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase","volume":"8","author":"Ganson","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rbre.2017.03.002_bib1015","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00296-014-3189-6","article-title":"Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis","volume":"35","author":"Castrejon","year":"2015","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rbre.2017.03.002_bib1020","doi-asserted-by":"crossref","first-page":"263720","DOI":"10.1155\/2014\/263720","article-title":"Allopurinol, benzbromarone, or a combination in treating patients with gout: analysis of a series of outpatients","volume":"2014","author":"Azevedo","year":"2014","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib1025","unstructured":"Doctoralia. Narcaricina - Indica\u00e7\u00f5es, posologia, efeitos adversos, perguntas frequentes. Accessed in 16\/02\/2015. Available in: http:\/\/www.doctoralia.com.br\/medicamento\/narcaricina-12626\/forum\/falta-do-medicamento-no-mercado-7053"},{"key":"10.1016\/j.rbre.2017.03.002_bib1030","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.140462","article-title":"Treatment of gout patients with impairment of renal function: a systematic literature review","volume":"92","author":"van Echteld","year":"2014","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.rbre.2017.03.002_bib1035","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4103\/0019-5154.77557","article-title":"A case series of allopurinol-induced toxic epidermal necrolysis","volume":"56","author":"Ranu","year":"2011","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib1040","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1590\/S0482-50042004000300013","article-title":"\u00d3bito decorrente da s\u00edndrome de hipersensibilidade ao alopurinol (SHA)","volume":"44","author":"Rachid","year":"2004","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib1045","first-page":"374","article-title":"A survey of current prescribing practices in gouty arthritis and symptomatic hyperuricemia in San Paulo, Brazil","volume":"21","author":"Ferraz","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rbre.2017.03.002_bib1050","doi-asserted-by":"crossref","first-page":"653e7","DOI":"10.1016\/j.amjmed.2015.01.013","article-title":"Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study","volume":"128","author":"Kim","year":"2015","journal-title":"Am J Med"}],"container-title":["Revista Brasileira de Reumatologia (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502117300214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2255502117300214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:21:07Z","timestamp":1719148867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2255502117300214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S2255502117300214"],"URL":"https:\/\/doi.org\/10.1016\/j.rbre.2017.03.002","relation":{},"ISSN":["2255-5021"],"issn-type":[{"value":"2255-5021","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical revision of the medical treatment of gout in Brazil","name":"articletitle","label":"Article Title"},{"value":"Revista Brasileira de Reumatologia (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbre.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.rbr.2016.06.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}